Zobrazeno 1 - 9
of 9
pro vyhledávání: '"John, Delehanty"'
Autor:
Fred T. Valentine, Sharon A. Riddler, Frances F. Haas, Donald W. Northfelt, David Henry, John Delehanty, Gary Richmond, Edwin DeJesus, Richard Haubrich, Prakash R. Sista, Ralph DeMasi, William G. Powderly, Melanie A. Thompson, David Wright, Miklos Salgo, Stephen Becker, Margrit Carlson, Peter R. Wolfe, Jacob Lalezari
Publikováno v:
Antiviral Therapy. 8:279-287
Enfuvirtide is a novel antiretroviral that blocks HIV-1 cell fusion and viral entry. This Phase II, controlled, open-label, randomized, multicentre dose-ranging trial explored the safety, antiviral activity and pharmacoki-netics of enfuvirtide, admin
Autor:
Jacob P, Lalezari, Edwin, DeJesus, Donald W, Northfelt, Gary, Richmond, Peter, Wolfe, Richard, Haubrich, David, Henry, William, Powderly, Stephen, Becker, Melanie, Thompson, Fred, Valentine, David, Wright, Margrit, Carlson, Sharon, Riddler, Frances F, Haas, Ralph, DeMasi, Prokash R, Sista, Miklos, Salgo, John, Delehanty
Publikováno v:
Antiviral therapy. 8(4)
Enfuvirtide is a novel antiretroviral that blocks HIV-1 cell fusion and viral entry. This Phase II, controlled, open-label, randomized, multicentre dose-ranging trial explored the safety, antiviral activity and pharmacokinetics of enfuvirtide, admini
Autor:
Ralph DeMasi, Jacob Lalezari, John Delehanty, Miklos Salgo, J. Michael Kilby, David Wheeler, Indravadan H. Patel, Joseph Wheat
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 30(2)
Background: Enfuvirtide, a HIV-1 membrane fusion inhibitor, is the first viral entry inhibitor approved for the treatment of HIV-1 infected patients in the USA. Parenteral administration of enfuvirtide in clinical trials has been safe and has resulte
Autor:
Antonella Castagna, Bonaventura Clotet, Jacques Reynes, Miklos Salgo, Ralph DeMasi, Mark T. Nelson, James Hui, Keith Henry, Sharon Walmsley, John Delehanty, Christine Katlama
Publikováno v:
The Journal of infectious diseases. 188(12)
The present study investigated the effect of enfuvirtide cross-reactive glycoprotein 41 (gp41) antibody on the efficacy or safety of enfuvirtide in patients participating in I of 2 24-week phase 3 clinical trials T-20 vs. optimized regimen only [TORO
Autor:
Sharon Walmsley, Peter J. Piliero, John Delehanty, Mary O'Hearn, Jacob Lalezari, Joseph J. Eron, Miklos Salgo, Jain Chung, Julio S. G. Montaner, Claude Drobnes, Calvin J. Cohen, Lucille Donatacci, Keith Henry, Daniel R. Kuritzkes, Benoit Trottier, Ralph DeMasi
Publikováno v:
The New England journal of medicine. 348(22)
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. Methods: Patients from 48 sites in the United States,
Autor:
Cynthia Wat, Keikawus Arastéh, Claude Drobnes, David A. Cooper, Ralph DeMasi, Miklos Salgo, John Delehanty, Mark Nelson, Jean François Delfraissy, Hans Jürgen Stellbrink, Joep M. A. Lange, Adriano Lazzarin, Les Huson, Bonaventura Clotet, Jacques Reynes, Christine Katlama
Publikováno v:
The New England journal of medicine, 348(22), 2186-2195. Massachussetts Medical Society
New England journal of medicine, 348(22), 2186-2195. Massachussetts Medical Society
New England journal of medicine, 348(22), 2186-2195. Massachussetts Medical Society
The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f12c15f0aebdfcc753b229ac3a52ea4
https://dare.uva.nl/personal/pure/en/publications/efficacy-of-enfuvirtide-in-patients-infected-with-drugresistant-hiv1-in-europe-and-australia(a7aabf5f-26f4-4ccf-b229-a969b4e6e58d).html
https://dare.uva.nl/personal/pure/en/publications/efficacy-of-enfuvirtide-in-patients-infected-with-drugresistant-hiv1-in-europe-and-australia(a7aabf5f-26f4-4ccf-b229-a969b4e6e58d).html
Autor:
Laurene H. Wang, Charles Wakeford, Melanie Thompson, Jeffrey N. Simpson, Donna Mildvan, Charles van der Horst, Jean Pierre Sommadossi, David H. Shepp, Franck Rousseau, James O. Kahn, John Delehanty, Joseph B. Quinn
Publikováno v:
The Journal of antimicrobial chemotherapy. 48(4)
Antiretroviral monotherapy for initial drug characterization risks the selection of resistant virus, yet monotherapy is the only setting where many fundamental properties of a new drug can be reliably determined. Using data on viral replication kinet
Publikováno v:
Mutation Research/Reviews in Genetic Toxicology. 167:215-232
Autor:
John Delehanty
Publikováno v:
Environmental Mutagenesis. 5:637-640